CRISPR Therapeutics Revenue

Biotechnology Research • Boston, Massachusetts, United States • 201-500 Employees

CRISPR Therapeutics revenue & valuation

Annual revenue	$38,100,000
Revenue per employee	$104,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$121,800,000
Total funding	$280,000,000

Key Contacts at CRISPR Therapeutics

Aamir Mir

Director, Crispr-X

Archana Swami

Director, Lnp Formulation Development, Technical Operations

Madhuri Agarwal

Director Regulatory Strategy, Global Regulatory Lead

Carlo Zambonelli

Director, Lnp Analytics

Demetrios Kalaitzidis

Head Of Hematology Research, Executive Director

Daren Crossman

Associate Director Automation

Stanley Oyaghire

Associate Director

Harmeet Gandhok

Director Of External Manufacturing

Eric Nottingham

Director, Quality Assurance Validation

Andrew Dunn

Director

Company overview

Headquarters	105 West First Street, Boston, MA 02127, US
Phone number	+141415613277
Website	crisprtx.com
NAICS	541714
SIC	283
Keywords	Hematology, Immuno-Oncology, Gene Editing
Founded	2013
Employees	201-500
Socials

CRISPR Therapeutics Email Formats

CRISPR Therapeutics uses 2 email formats. The most common is {first initial}.{last name} (e.g., j.doe@crisprtx.com), used 78.4% of the time.

Format	Example	Percentage
{first initial}.{last name}	j.doe@crisprtx.com	78.4%
{first name}.{last name}	john.doe@crisprtx.com	20.1%

About CRISPR Therapeutics

Since its inception over a decade ago, CRISPR Therapeutics has evolved from a research-stage company advancing gene editing programs into a leader that celebrated the historic approval of the first-ever CRISPR-based therapy. The Company has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. In 2018, CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic to investigate the treatment of sickle cell disease and transfusion-dependent beta thalassemia. Beginning in late 2023, CASGEVY® (exagamglogene autotemcel [exa-cel]) was approved in several countries to treat eligible patients with either of these conditions. The Nobel Prize-winning CRISPR technology has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts, CRISPR Therapeutics has formed strategic partnerships with leading companies including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California.

Employees by Management Level

Total employees: 201-500

Seniority

Employees

Entry

Director

Senior

Employees by Department

CRISPR Therapeutics has 184 employees across 11 departments.

Departments

Number of employees

Funding Data

Explore CRISPR Therapeutics's funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount	Link to Article
2021-01-14	9	N/A
2024-03-13	14	$280,000,000

Funding Insights

$280,000,000

Total funding amount

$280,000,000

Most recent funding amount

Number of funding rounds

CRISPR Therapeutics Tech Stack

Discover the technologies and tools that power CRISPR Therapeutics's digital infrastructure, from frameworks to analytics platforms.

Adobe Fonts

Font scripts

jQuery

JavaScript libraries

Google Tag Manager

Tag managers

Nginx

Reverse proxies

Apple iCloud Mail

Webmail

PHP

Programming languages

Font Awesome

Font scripts

Open Graph

Miscellaneous

Vimeo

Video players

Yii

Web frameworks

ZURB Foundation

UI frameworks

Google Analytics

Analytics

Frequently asked questions

CRISPR Therapeutics is located in Boston, Massachusetts, US.

You can reach CRISPR Therapeutics at +141415613277.

CRISPR Therapeutics generates an estimated annual revenue of $38,050,000. This revenue figure reflects the company's market position and business performance in its industry.

CRISPR Therapeutics has an estimated valuation of $121,800,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

CRISPR Therapeutics was founded in 2013, making it 13 years old. The company has established itself as a significant player in its industry over this time.

CRISPR Therapeutics has approximately 201-500 employees. The company continues to grow its workforce to support its business operations and expansion.

CRISPR Therapeutics has raised a total of $280,000,000 across 2 funding rounds. This investment has helped the company grow and expand its operations.